Statistics from Altmetric.com
The Authors' reply We have read with interest the comments by Bin Abdulhak and colleagues1 to our recently published article.2 We share the same opinion concerning the use of dabigatran in this setting. Thus, in our article we have proposed the same posology in face of the similar findings: despite the lack of conclusive evidence in support of any particular dabigatran dosage or timing for interrupting or restarting drug therapy, like Bin Abdulhak and colleagues,1 …
Contributors RP has prepared the response to the letter which was revised and completed with suggestions of the three remaining authors. All authors approved the final version.
Competing interests RP has received honoraria for serving as a speaker and consultant for Boheringher-Ingelheim and as a co-investigator in the ENGAGE-AF TIMI 48 trial. There are no conflicts of interest by other coauthors.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.